1219130-57-0

Basic information

• Product Name: 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one
• Synonyms: 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one;3(4H)-Oxo-2H-benzo[b][1,4]oxazin-7-boronic acid pinacol ester;2H-1,4-benzoxazin-3(4H)-one, 7-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;7-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-3,4- dihydro-2H-1,4-benzoxazin-3-one;3-Oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-boronic acid pinacol ester;7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4H-1,4-benzoxazin-3-one
• CAS NO: 1219130-57-0
• Molecular Formula: C14H18BNO4
• Molecular Weight: 275
• EINECS: 200-582-5
• Product Categories: Organic boronic acid
• Mol File: 1219130-57-0.mol

Chemical Properties

• Boiling Point: 444.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.20
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 12.80±0.20(Predicted)
• CAS DataBase Reference: 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one(1219130-57-0)
• EPA Substance Registry System: 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one(1219130-57-0)

Safety Data

• Hazardous Substances Data: 1219130-57-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one is used as a precursor in Suzuki-Miyaura cross-coupling reactions for the formation of carbon-carbon bonds, a common method in organic synthesis. The presence of the dioxaborolan-2-yl group makes it a versatile building block for creating a variety of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one is used as a potential lead compound for the development of new drugs. Its benzo[b][1,4]oxazin-3(4H)-one group suggests that it may exhibit biological activity, particularly in the areas of antimicrobial and anticancer properties. Further research is necessary to explore its full potential and therapeutic applications.
Used in Material Science:
Although not explicitly mentioned in the provided materials, the compound's unique structure may also find applications in material science, potentially contributing to the development of new materials with specific properties, such as improved stability or reactivity in certain conditions. Further investigation would be required to determine its suitability and performance in this field.

Upstream product

• 27684-84-0 5-bromo-2-nitrophenol 
• 38191-34-3 2-amino-5-bromophenol 
• 73183-34-3 bis(pinacol)diborane 
• 321436-06-0 7-bromo-3,4-dihydro-2H-1,4-benzoxazin-3-one 

Downstream Products

• 67193-97-9 7-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 1489264-77-8 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-1,4-benzoxazin-3(4H)-one 

Relevant articles and documents

SYK INHIBITORS

The present disclosure a Syk compound inhibitors, including state cancer and inflammation and various disease States thereof in the treatment of relates to the use of. In one aspect a particular embodiment, . given by formula I which is marked as a chemical structure of compound. In formula said, X 1, X 2, X 3, R 2, R 3, R 4, R 5, and Y has described herein is. The present disclosure of a formula I compounds or a pharmaceutically acceptable salt of pharmaceutical compositions including, mediated by Syk and to treat conditions a employing these compounds and compositions further provides a method. (by machine translation)

Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors

Vascular endothelial growth factor receptor-2 (VEGFR-2) plays an important role in tumor angiogenesis, and inhibition of the VEGFR-2 signaling pathway has emerged as an attractive strategy for the treatment of cancer. Herein, we describe the design, synthesis, and biological evaluation of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors. Among the new derivatives, compound 3k exhibited high VEGFR-2 inhibitory potency in both enzymatic and VEGF-induced HUVEC cellular proliferation assays (IC50 = 0.5 and 9.8 nM, respectively). Kinase selectivity profiling revealed that 3k was a highly selective VEGFR-2 inhibitor. Moreover, 3k effectively inhibited angiogenesis in HUVEC tube formation assay.

HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT

Novel heterocyclic biaryl derivatives were disclosed which are useful as pharmaceutical agents and which exhibit a phosphodiesterase-inhibitory action. The heterocyclic biaryl derivatives are represented by the following general formula (1): wherein the H

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.